ANDAINJECTIONINJECTABLE
Approved
Feb 2008
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
6
Clinical Trials (5)
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Started Mar 2018
40 enrolled
Refractory or Recurrent Solid TumorsRhabdomyosarcomaNon-Rhabdomyosarcoma Soft Tissue Sarcoma+1 more
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
Started Mar 2016
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Started Jun 2014
44 enrolled
Metastatic CancerUnspecified Adult Solid Tumor
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
Started Feb 2013
33 enrolled
BRAF NP_004324.2:p.V600XKRAS wt AlleleMetastatic Malignant Solid Neoplasm+4 more
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Started Feb 2013
73 enrolled
GanglioneuroblastomaRecurrent Neuroblastoma